Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Twist Bioscience

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TB202-3

            Therapeutic Area: Infections and Infectious Diseases Product Name: TB202-3

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            The data shows that TB202-3 and TB202-63, both single domain VHH “nanobodies,” protect against weight loss, a key indicator of disease severity, at the lowest dose of 1 mg/kg in a preclinical hamster challenge model.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAR-T cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Neogene

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 13, 2020

            Details:

            The companies will leverage Neogene’s expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells together with Twist’s DNA synthesis platform and product lines to develop personalized CAR) T cell therapies and TCR therapies for patients with cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bispecific antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Seismic Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 04, 2020

            Details:

            Twist Biopharma will use Hyperimmune Libraries, two fully human antibody libraries focused on the heavy chain complementary determining region 3 (CDR3) loop diversity involved in antigen recognition, to identify antibodies that bind to the specified immuno-oncology targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SARS-CoV-2 S1 Antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 28, 2020

            Details:

            The Twist anti-SARS-CoV-2 S1 Antibody Panel includes 32 human antibodies that bind with picomolar to nanomolar affinity to S1 spike protein on the SARS-CoV-2 virus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Invetx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 16, 2020

            Details:

            Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 08, 2020

            Details:

            Under the pact Takeda will tap the Twist Bioscience's phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics across its four core areas: oncology, rare diseases, neuroscience and gastroenterology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neutralizing antibody therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Proteona

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2020

            Details:

            The international alliance was initiated by Proteona in response to the urgent need of patients most at risk facing the pandemic. The alliance aims to develop antibody therapies to provide a safe and targeted treatment for these vulnerable populations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Synthetic genes

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vanderbilt University Medical Center

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 26, 2020

            Details:

            Twist Biopharma, will provide custom antibody drug discovery libraries and will screen the libraries for potential antibody therapeutics that would treat patients with COVID-19.